CA2592605A1 - Method for stabilizing anti-dementia drug - Google Patents

Method for stabilizing anti-dementia drug Download PDF

Info

Publication number
CA2592605A1
CA2592605A1 CA002592605A CA2592605A CA2592605A1 CA 2592605 A1 CA2592605 A1 CA 2592605A1 CA 002592605 A CA002592605 A CA 002592605A CA 2592605 A CA2592605 A CA 2592605A CA 2592605 A1 CA2592605 A1 CA 2592605A1
Authority
CA
Canada
Prior art keywords
molecular weight
high molecular
dementia drug
substance
acidic substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002592605A
Other languages
French (fr)
Other versions
CA2592605C (en
Inventor
Yosuke Ueki
Yasuyuki Suzuki
Satoshi Fujioka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co., Ltd.
Yosuke Ueki
Yasuyuki Suzuki
Satoshi Fujioka
Eisai Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36615033&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2592605(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai R&D Management Co., Ltd., Yosuke Ueki, Yasuyuki Suzuki, Satoshi Fujioka, Eisai Co., Ltd. filed Critical Eisai R&D Management Co., Ltd.
Publication of CA2592605A1 publication Critical patent/CA2592605A1/en
Application granted granted Critical
Publication of CA2592605C publication Critical patent/CA2592605C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The present invention provides a method for stabilizing an anti-dementia drug in a pharmaceutical composition containing the anti-dementia drug and a high molecular weight basic substance by adding a high molecular weight acidic substance to said pharmaceutical composition. Further, the present invention provides a pharmaceutical composition containing an anti-dementia drug and a high molecular basic substance in which a high molecular weight acidic substance is contained for stabilizing the anti-dementia drug. Furthermore, the present invention provides a method for manufacturing a pharmaceutical composition which comprises steps wherein a solution or suspension containing a high molecular weight acidic substance is added to a mixture of an anti-dementia drug and a high molecular weight basic substance for the sake of stabilizing the anti-dementia drug.

Claims (31)

1. A method for stabilizing an anti-dementia drug, comprising adding a high molecular weight acidic substance into a pharmaceutical composition comprising the anti-dementia drug and a high molecular weight basic substance.
2. The method according to Claim 1, wherein the high molecular weight acidic substance is added in an amount that degradation product of the anti-dementia drug which are produced by contact between the anti-dementia drug and the high molecular weight basic substance can be suppressed.
3. The method according to Claim 1 or 2, wherein the anti-dementia drug is a compound having a tertiary amino group.
4. The method according to any one of Claims 1 to 3, wherein the anti-dementia drug is selected from the group consisting of rivastigmine, galantamine, donepezil, 3-[1-(phenylmethyl)piperidin-4-yl]-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)-1-propane and 5,7-dihydro-3-[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]-6H-pyrrolo[4,5-f]-1,2-benzisoxazol-6-one and pharmaceutically acceptable salts thereof.
5. The method according to any one of Claims 1 to 4, wherein the anti-dementia drug is donepezil or a pharmaceutically acceptable salt thereof.
6. The method according to any one of Claims 1 to 5, wherein the high molecular weight basic substance is a water-insoluble polymer substance.
7. The method according to any one of Claims 1 to 6, wherein the high molecular weight basic substance is at least one selected from the group consisting of ethylcellulose, ethyl acrylate-methyl methacrylate copolymer and polyethylene oxide.
8. The method according to any one of Claims 1 to 7, wherein the high molecular weight acidic substance is an enteric polymer substance.
9. The method according to any one of Claims 1 to 8, wherein the high molecular weight acidic substance is at least one selected from the group consisting of methacrylic acid-ethyl acrylate copolymer, methacrylic acid-methyl methacrylate copolymer, hydroxypropyl methylcellulose phthalate and hydroxypropyl methylcellulose acetate succinate.
10. The method according to any one of Claims 1 to 9, further comprising adding at least one of a low molecular weight acidic substance and an anti-oxidant.
11. The method according to Claim 10, wherein the low molecular weight acidic substance is at least one selected from the group consisting of carboxylic acids, sulfonic acids, hydroxy acids, acidic amino acids and inorganic acids.
12. The method according to Claim 10 or 11, wherein the low molecular weight acidic substance is at least one selected from the group consisting of hydroxy acids, acidic amino acids and inorganic acids.
13. The method according to any one of Claims 10 to 12, wherein the low molecular weight acidic substance is at least one selected from the group consisting of succinic acid, tartaric acid, citric acid, fumaric acid, maleic acid, malic acid, aspartic acid, glutamic acid, glutamic acid hydrochloride, hydrochloric acid and phosphoric acid.
14. The method according to any one of Claims 10 to 13, wherein the low molecular weight acidic substance is at least one selected from the group consisting of succinic acid, tartaric acid, citric acid, malic acid, aspartic acid, glutamic acid, glutamic acid hydrochloride, hydrochloric acid and phosphoric acid.
15. The method according to any one of Claims 10 to 14, wherein the anti-oxidant is at least one selected from the group consisting of ascorbic acids, sulfur-containing amino acids, hydroquinone derivatives and tocopherols.
16. A use of a high molecular weight acidic substance for suppressing degradation product of an anti-dementia drug produced by contact between the anti-dementia drug and a high molecular weight basic substance.
17. A use of a high molecular weight acidic substance and at least one of a low molecular weight acidic substance and an anti-oxidant for suppressing degradation product of an anti-dementia drug produced by contact between the anti-dementia drug and a high molecular weight basic substance.
18. A pharmaceutical composition comprising an anti-dementia drug and a high molecular weight basic substance, wherein the composition further comprises a high molecular weight acidic substance for stabilizing the anti-dementia drug.
19. The pharmaceutical composition according to Claim 18, further comprising at least one of a low molecular weight acidic substance and an anti-oxidant for stabilizing the anti-dementia drug.
20. The pharmaceutical composition according to Claim 18, wherein the composition comprises a matrix comprising a mixture of the anti-dementia drug, the high molecular weight basic substance and the high molecular weight acidic substance for stabilizing the anti-dementia drug.
21. The pharmaceutical composition according to Claim 20, wherein at least one of a low molecular weight acidic substance and an anti-oxidant for stabilizing the anti-dementia drug is mixed into the matrix.
22. The pharmaceutical composition according to Claim 18, wherein the pharmaceutical composition comprises a core comprising the anti-dementia drug and a coating layer comprising the high molecular weight basic substance which covers the core, and wherein the high molecular weight acidic substance is mixed into at least one of the core and the coating layer.
23. The pharmaceutical composition according to Claim 22, wherein at least one of a low molecular weight acidic substance and an anti-oxidant for stabilizing the anti-dementia drug is further mixed into at least one of the core and the coating layer.
24. The pharmaceutical composition according to any one of Claims 18 to 23, wherein the pharmaceutical composition is a sustained-release preparation.
25. The pharmaceutical composition according to any one of Claims 18 to 24, wherein the high molecular weight acidic substance is an enteric polymer substance.
26. A matrix type sustained-release preparation comprising:
donepezil or a pharmaceutically acceptable salt thereof;
a high molecular weight basic substance; and a high molecular weight acidic substance.
27. The matrix type sustained-release preparation according to claim 26, further comprising at least one of a low molecular weight acidic substance and an anti-oxidant.
28. A method for manufacturing a pharmaceutical composition, comprising the steps of:
mixing an anti-dementia drug and a high molecular weight basic substance;
and granulating the mixture, wherein a high molecular weight acidic substance for stabilizing the anti-dementia drug is added to the mixture of the anti-dementia drug and the high molecular weight basic substance during at least one of the mixing step and the granulating step.
29. The method according to Claim 28, wherein the high molecular weight acidic substance is added as a powder.
30. The method according to claim 28 or 29, wherein at least one of a low molecular weight acidic substance and an anti-oxidant for stabilizing the anti-dementia drug is further added to the mixture of the anti-dementia drug and the high molecular weight basic substance during at least one of the mixing step and the granulating step.
31. The method according to Claim 29, wherein at least one of the low molecular weight acidic substance and the anti-oxidant is added as a solution or suspension.
CA2592605A 2004-12-27 2005-12-27 Method for stabilizing anti-dementia drug Expired - Fee Related CA2592605C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2004376770 2004-12-27
JP2004-376770 2004-12-27
JP2005041492 2005-02-18
JP2005-041492 2005-02-18
PCT/JP2005/024254 WO2006070930A1 (en) 2004-12-27 2005-12-27 Method for stabilizing anti-dementia drug

Publications (2)

Publication Number Publication Date
CA2592605A1 true CA2592605A1 (en) 2006-07-06
CA2592605C CA2592605C (en) 2010-12-07

Family

ID=36615033

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2592605A Expired - Fee Related CA2592605C (en) 2004-12-27 2005-12-27 Method for stabilizing anti-dementia drug

Country Status (14)

Country Link
US (2) US8481565B2 (en)
EP (1) EP1830886B1 (en)
JP (2) JP2008525313A (en)
KR (1) KR100866720B1 (en)
AU (1) AU2005320547B2 (en)
BR (1) BRPI0518396A2 (en)
CA (1) CA2592605C (en)
HK (1) HK1112399A1 (en)
IL (1) IL183650A (en)
MX (1) MX2007007836A (en)
NO (1) NO20073482L (en)
NZ (1) NZ555693A (en)
RU (1) RU2401125C2 (en)
WO (1) WO2006070930A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
MX2007007836A (en) 2004-12-27 2007-08-20 Eisai R&D Man Co Ltd Method for stabilizing anti-dementia drug.
US20070129402A1 (en) * 2004-12-27 2007-06-07 Eisai Research Institute Sustained release formulations
US20090023778A1 (en) * 2005-04-28 2009-01-22 Eisai R&D Management Co., Ltd. Composition Containing Anti-Dementia Drug
WO2008066183A1 (en) * 2006-12-01 2008-06-05 Nitto Denko Corporation Skin adhesive preparation comprising stabilized donepezil
KR20090086565A (en) * 2006-12-01 2009-08-13 닛토덴코 가부시키가이샤 Skin adhesive preparation comprising stabilized donepezil
JP5037523B2 (en) * 2006-12-01 2012-09-26 日東電工株式会社 Method for suppressing coloration of donepezil-containing patch preparation, and method for reducing the amount of donepezil related substances produced
CN101605545B (en) * 2006-12-01 2011-10-05 日东电工株式会社 Skin adhesive preparation comprising stabilized donepezil
EP2127651A4 (en) * 2007-01-19 2012-08-01 Eisai R&D Man Co Ltd Stabilized medicinal composition containing donepezil, method of producing the same and method for stabilization
GR20070100405A (en) * 2007-06-26 2009-01-20 Genepharm �.�. Improved pharmaceutical composition containing acetylcholine esterace inhibitor and method for the preparation thereof
ES2634421T3 (en) 2008-03-27 2017-09-27 Chase Pharmaceuticals Corporation Use and composition to treat dementia
DE102009041839A1 (en) * 2009-09-18 2011-03-24 Dolorgiet Gmbh & Co. Kg Preparation of a donepezil-containing tablet, useful for treating mild to moderate dementia of the Alzheimer type, comprises wet granulation of donepezil with granulating liquid and excipients e.g. cellulose and starch
US8962014B2 (en) * 2009-12-22 2015-02-24 Acino Ag Transdermal therapeutic system for administering rivastigmine or derivatives thereof
US10076502B2 (en) 2009-12-22 2018-09-18 Luye Pharma Ag Transdermal therapeutic system for administering rivastigmine or derivatives thereof
US20120294947A1 (en) * 2009-12-28 2012-11-22 Nipro Corporation Oral Preparation Having Improved Quality
US20110218216A1 (en) * 2010-01-29 2011-09-08 Kumaravel Vivek Extended release pharmaceutical composition of donepezil
JP5749247B2 (en) * 2010-02-22 2015-07-15 第一三共株式会社 Oral sustained-release solid preparation
EP2366378A1 (en) 2010-03-01 2011-09-21 Dexcel Pharma Technologies Ltd. Sustained-release donepezil formulations
JP2011213606A (en) * 2010-03-31 2011-10-27 Sawai Pharmaceutical Co Ltd Method for producing solid preparation containing donepezil
US20140004189A1 (en) * 2011-01-25 2014-01-02 Cadila Healthcare Limited Modified release pharmaceutical compositions memantine
JP5656258B2 (en) * 2011-03-09 2015-01-21 塩野義製薬株式会社 Orally disintegrating tablets containing galantamine
EP2502620A1 (en) 2011-03-24 2012-09-26 Krka Tovarna Zdravil, D.D., Novo Mesto Solid pharmaceutical composition comprising donepezil
CN103417490B (en) * 2012-05-21 2015-06-17 成都康弘药业集团股份有限公司 Granule containing donepezil and preparation method thereof
BR112015020773A2 (en) * 2013-02-28 2017-07-18 Lupin Ltd timed release pharmaceutical composition
KR102241113B1 (en) 2013-02-28 2021-04-15 루핀 리미티드 Pharmaceutical compositions of donepezil having specific in vitro dissolution profile or pharmacokinetics parameters
KR101990951B1 (en) * 2015-04-27 2019-06-20 주식회사 네비팜 A sustained releasing Pharmaceutical Composition comprising Rivastigmine
KR101938872B1 (en) * 2016-09-30 2019-01-16 주식회사 바이오파마티스 Composition comprising complex for prevention and treatment of dementia and cognitive impairment
CN110662534A (en) 2017-05-31 2020-01-07 勃林格殷格翰国际有限公司 Pharmaceutical compositions and dosage forms comprising (E) -4- (2- (aminomethyl) -3-fluoroallyloxy) -N-tert-butylbenzamide, processes for their preparation, methods of treatment and uses thereof
KR102115102B1 (en) 2018-12-21 2020-05-26 동아에스티 주식회사 Percutaneous Absorption Preparation Comprising Stabilized Donepezil

Family Cites Families (227)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1894239A (en) * 1930-01-20 1933-01-10 Ig Farbenindustrie Ag Production of molybdenum and tungsten carbonyls
US2327996A (en) 1941-11-24 1943-08-31 Thompson W Burnam Process of dehydrating mineral oil emulsions
HU187215B (en) * 1983-01-26 1985-11-28 Egyt Gyogyszervegyeszeti Gyar Method for producing pharmaceutical product of high actor content and prolonged effect
IL72381A (en) * 1983-07-20 1988-03-31 Sanofi Sa Pharmaceutical composition based on valproic acid
SE452177B (en) 1983-09-30 1987-11-16 Nils Anders Lennart Wikdahl DEVICE FOR FRACTIONING FIBER SUSPENSIONS
SE457505B (en) 1984-01-10 1989-01-09 Lejus Medical Ab LAMINATED ORAL PHARMACEUTICAL COMPOSITION AND PROCEDURES FOR ITS PREPARATION
DK62184D0 (en) 1984-02-10 1984-02-10 Benzon As Alfred DIFFUSION COATED POLYDEPOT PREPARATION
US4772475A (en) 1985-03-08 1988-09-20 Yamanouchi Pharmaceutical Co., Ltd. Controlled-release multiple units pharmaceutical formulation
NL8500724A (en) 1985-03-13 1986-10-01 Univ Groningen DEVICES FOR REGULAR RELEASE OF ACTIVE SUBSTANCES AND METHOD OF MANUFACTURE THEREOF
US4892742A (en) * 1985-11-18 1990-01-09 Hoffmann-La Roche Inc. Controlled release compositions with zero order release
IL81419A0 (en) 1986-01-30 1987-08-31 Syntex Inc Long acting sustained release pharmaceutical compositions containing dihydropyridines and their preparation
US4940556A (en) * 1986-01-30 1990-07-10 Syntex (U.S.A.) Inc. Method of preparing long acting formulation
IE63321B1 (en) 1986-02-03 1995-04-05 Elan Corp Plc Drug delivery system
US4832957A (en) * 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
NL8701335A (en) * 1986-06-21 1988-01-18 Sandoz Ag ORAL PHARMACEUTICAL PREPARATIONS.
US4970075A (en) 1986-07-18 1990-11-13 Euroceltique, S.A. Controlled release bases for pharmaceuticals
US4710384A (en) 1986-07-28 1987-12-01 Avner Rotman Sustained release tablets made from microcapsules
CA1308357C (en) * 1987-01-28 1992-10-06 Tohru Chiba Method for the preparation of a coated solid medicament
US4851232A (en) * 1987-02-13 1989-07-25 Alza Corporation Drug delivery system with means for obtaining desirable in vivo release rate pattern
US4968508A (en) 1987-02-27 1990-11-06 Eli Lilly And Company Sustained release matrix
US4894239A (en) * 1987-06-02 1990-01-16 Takeda Chemical Industries, Ltd. Sustained-release preparation and production thereof
EP0297866A3 (en) 1987-07-01 1989-12-13 The Boots Company PLC Therapeutic agents
US4792452A (en) 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
US4891223A (en) * 1987-09-03 1990-01-02 Air Products And Chemicals, Inc. Controlled release delivery coating formulation for bioactive substances
JP2643222B2 (en) * 1988-02-03 1997-08-20 エーザイ株式会社 Multi-layer granules
US5254347A (en) 1988-03-31 1993-10-19 Tanabe Seiyaku Co., Ltd. Controlled release pharmaceutical preparation and method for producing the same
JPH0768125B2 (en) * 1988-05-18 1995-07-26 エーザイ株式会社 Oral formulation of acid labile compounds
DE3818207A1 (en) 1988-05-28 1989-11-30 Bosch Gmbh Robert TIRE PRESSURE AND TEMPERATURE SENSOR
DE3827214A1 (en) * 1988-08-11 1990-02-15 Roehm Gmbh RETARDED MEDICAMENT AND METHOD FOR THE PRODUCTION THEREOF
JP2514078B2 (en) * 1988-08-22 1996-07-10 エスエス製薬株式会社 Compressed formulation
JP2893191B2 (en) * 1988-11-08 1999-05-17 武田薬品工業株式会社 Controlled release matrix agent
AU645003B2 (en) 1988-11-08 1994-01-06 Takeda Chemical Industries Ltd. Sustained release preparations
US5202128A (en) * 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5278474A (en) * 1989-01-12 1994-01-11 Tokyo Densoku Kabushiki Kaisha Discharge tube
ES2077023T3 (en) 1989-03-10 1995-11-16 Yamanouchi Pharma Co Ltd COATING MATERIAL THAT CONTROLS THE RELEASE OF A MEDICINAL PRODUCT FOR FORMULATIONS OF PROLONGED ACTIVITY.
NZ233403A (en) * 1989-04-28 1992-09-25 Mcneil Ppc Inc Simulated capsule-like medicament
JP2572673B2 (en) 1990-07-25 1997-01-16 エスエス製薬株式会社 Sustained-release tablets
US5102668A (en) * 1990-10-05 1992-04-07 Kingaform Technology, Inc. Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5656295A (en) 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
HU9203780D0 (en) 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
US5681585A (en) * 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
DE4225730C2 (en) * 1992-08-04 2003-04-30 Merz Pharma Gmbh & Co Kgaa Process for the preparation of solid dosage forms with protracted 2-stage release
IT1258143B (en) 1992-09-11 1996-02-20 Alfa Wassermann Spa PROGRAMMED SALE TABS CONTAINING NAPROXEN
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5455046A (en) 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5662933A (en) 1993-09-09 1997-09-02 Edward Mendell Co., Inc. Controlled release formulation (albuterol)
KR950007873A (en) * 1993-09-20 1995-04-15 후꾸하라 요시하루 Biologics Sustained-Release Pharmaceutical Formulations
US5500227A (en) * 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
JP3071467B2 (en) 1993-12-29 2000-07-31 メルク シヤープ エンド ドーム リミテツド Substituted morpholine derivatives and their use as therapeutic agents
AT403988B (en) 1994-05-18 1998-07-27 Lannacher Heilmittel SOLID ORAL RETARDED PREPARATION
US5698224A (en) * 1994-06-27 1997-12-16 Alza Corporation Tacrine therapy
JPH0826977A (en) * 1994-07-19 1996-01-30 Tanabe Seiyaku Co Ltd Elution-controlled type oral preparation
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US20020006438A1 (en) 1998-09-25 2002-01-17 Benjamin Oshlack Sustained release hydromorphone formulations exhibiting bimodal characteristics
US5871776A (en) * 1995-01-31 1999-02-16 Mehta; Atul M. Controlled-release nifedipine
US6083532A (en) * 1995-03-01 2000-07-04 Duramed Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers and tablet formed therefrom
FI98343C (en) 1995-03-21 1997-06-10 Orion Yhtymae Oy Oral formulation
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
US5840332A (en) 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
IT1282650B1 (en) * 1996-02-19 1998-03-31 Jagotec Ag PHARMACEUTICAL TABLET, CHARACTERIZED BY A HIGH INCREASE IN VOLUME IN CONTACT WITH BIOLOGICAL LIQUIDS
US5773031A (en) * 1996-02-27 1998-06-30 L. Perrigo Company Acetaminophen sustained-release formulation
US6245351B1 (en) * 1996-03-07 2001-06-12 Takeda Chemical Industries, Ltd. Controlled-release composition
JPH09323926A (en) * 1996-03-15 1997-12-16 Nikken Chem Co Ltd Sustained release tablet of sodium valproate
US6156340A (en) 1996-03-29 2000-12-05 Duquesne University Of The Holy Ghost Orally administrable time release drug containing products
US6096339A (en) 1997-04-04 2000-08-01 Alza Corporation Dosage form, process of making and using same
JP2000511161A (en) * 1996-05-24 2000-08-29 アンジオテック ファーマシュウティカルズ,インコーポレイテッド Compositions and methods for treating or preventing diseases of the body passages
TW513409B (en) 1996-06-07 2002-12-11 Eisai Co Ltd Polymorphs of donepezil hydrochloride
DE19630035A1 (en) 1996-07-25 1998-01-29 Asta Medica Ag Tramadol multiple unit formulations
AUPO274596A0 (en) 1996-10-04 1996-10-31 Armstrong, Stuart Maxwell Method for the treatment of neurological or neuropsychiatric disorders
US6310085B1 (en) 1997-10-03 2001-10-30 Clarencew Pty Ltd. Method for the treatment of neurological or neuropsychiatric disorders
IT1289160B1 (en) * 1997-01-08 1998-09-29 Jagotec Ag FULLY COATED PHARMACEUTICAL TABLET FOR THE CONTROLLED RELEASE OF ACTIVE INGREDIENTS WHICH PRESENT PROBLEMS OF
DE19707655A1 (en) 1997-02-26 1998-08-27 Hoechst Ag Combination preparation for use in dementia
CA2216215A1 (en) 1997-04-05 1998-10-05 Isa Odidi Controlled release formulations using intelligent polymers having opposing wettability characteristics of hydrophobicity and hydrophilicity
US6210710B1 (en) * 1997-04-28 2001-04-03 Hercules Incorporated Sustained release polymer blend for pharmaceutical applications
US7008950B1 (en) * 1997-06-05 2006-03-07 Takeda Chemical Industries, Ltd. Benzofurans as suppressors of neurodegeneration
TW446561B (en) * 1997-06-30 2001-07-21 Dev Center Biotechnology Improved stabilization of prostaglandin drug
FR2766708B1 (en) * 1997-07-30 2000-05-05 Galenix Dev COMPOSITION CONTAINING HYDROXYPROPYLCELLULOSE, HYDROXYPROPYLMETHYLCELLULOSE AND / OR ETHYLCELLULLOSE AS DISINTEGRANTS, AND PROCESS FOR OBTAINING SAME
JP3797764B2 (en) * 1997-10-01 2006-07-19 エーザイ株式会社 Light stabilizing composition
US20030092737A1 (en) * 1997-11-14 2003-05-15 Pierre Maffrand Jean Combination of active ingredients for the treatment of senile dementia of the Alzheimer type
US20040028735A1 (en) * 1997-11-14 2004-02-12 Unchalee Kositprapa Pharmaceutical formulation
CO4980891A1 (en) 1997-11-14 2000-11-27 Sanofi Sa ASSOCIATION OF ACTIVE PRINCIPLES FOR THE TREATMENT OF SENILE DEMENTIA OF THE AZHEIMER TYPE
FR2772615B1 (en) 1997-12-23 2002-06-14 Lipha MULTILAYER TABLET FOR INSTANT RELEASE THEN PROLONGED ACTIVE SUBSTANCES
US6251430B1 (en) * 1998-02-04 2001-06-26 Guohua Zhang Water insoluble polymer based sustained release formulation
JP3987655B2 (en) 1998-03-03 2007-10-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 Transdermal preparation or suppository containing an anti-dementia drug
US6372254B1 (en) * 1998-04-02 2002-04-16 Impax Pharmaceuticals Inc. Press coated, pulsatile drug delivery system suitable for oral administration
AU3024399A (en) * 1998-04-03 1999-10-25 Bm Research A/S Controlled release composition
US6262081B1 (en) * 1998-07-10 2001-07-17 Dupont Pharmaceuticals Company Composition for and method of treating neurological disorders
UA73092C2 (en) * 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Tablets with enteric coating and method for their manufacture
EP1101490B1 (en) 1998-07-28 2005-04-13 Tanabe Seiyaku Co., Ltd. Preparation capable of releasing drug at target site in intestine
EP1025858A4 (en) * 1998-08-28 2009-03-11 Eisai R&D Man Co Ltd Medicinal compositions with relieved bitterness, etc.
DE19842753A1 (en) 1998-09-18 2000-03-23 Bayer Ag Multiple-unit retard oral dosage formulation having controlled release independent of agitation and food effect, containing particles of combination of drug and hydroxypropyl cellulose
US6531152B1 (en) * 1998-09-30 2003-03-11 Dexcel Pharma Technologies Ltd. Immediate release gastrointestinal drug delivery system
US6322819B1 (en) 1998-10-21 2001-11-27 Shire Laboratories, Inc. Oral pulsed dose drug delivery system
WO2000024423A1 (en) * 1998-10-26 2000-05-04 Tanabe Seiyaku Co., Ltd. Sustained-release particles
US6797283B1 (en) * 1998-12-23 2004-09-28 Alza Corporation Gastric retention dosage form having multiple layers
HUP0104778A3 (en) * 1998-12-24 2004-05-28 Janssen Pharmaceutica Nv Controlled release galantamine composition
US6659463B2 (en) 1999-01-08 2003-12-09 Thomas J. Mackey Interconnecting miniature toy figurine bases with record tracking system
DE19901040A1 (en) 1999-01-14 2000-07-20 Knoll Ag Controlled release dosage forms containing active ingredients which are readily soluble in water
EP1027886B1 (en) 1999-02-10 2008-07-09 Pfizer Products Inc. Pharmaceutical solid dispersions
ES2310164T3 (en) 1999-02-10 2009-01-01 Pfizer Products Inc. LIBERATION DEVICE CONTROLLED BY THE MATRIX.
US6706283B1 (en) * 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
ATE313319T1 (en) * 1999-03-31 2006-01-15 Janssen Pharmaceutica Nv PREGELATINATED STARCH IN A CONTROLLED RELEASE FORMULATION
EP1086706B1 (en) 1999-03-31 2003-11-26 Eisai Co., Ltd. Stabilized compositions containing nootropic drugs
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US7919119B2 (en) * 1999-05-27 2011-04-05 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6632451B2 (en) 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system
AU781048B2 (en) 1999-09-02 2005-05-05 Nostrum Pharmaceuticals, Inc. Controlled release pellet formulation
GB9923045D0 (en) * 1999-09-29 1999-12-01 Novartis Ag New oral formulations
US20020107173A1 (en) * 1999-11-04 2002-08-08 Lawrence Friedhoff Method of treating amyloid beta precursor disorders
IL133196A0 (en) * 1999-11-29 2001-03-19 Yissum Res Dev Co Gastroretentive controlled release pharmaceutical dosage forms
US20030124176A1 (en) * 1999-12-16 2003-07-03 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
BR0007360A (en) * 1999-12-23 2001-08-14 Johnson & Johnson Controlled release composition
US6627223B2 (en) 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
US20030144255A1 (en) * 2000-03-06 2003-07-31 Bain Allen I Compositions for prevention and treatment of dementia
DE10013029A1 (en) 2000-03-17 2001-09-20 Roehm Gmbh Multilayer formulation for controlled drug release in colon, comprising drug-containing core having inner and outer coatings of acrylic copolymers with quaternary ammonium and anionic groups respectively
IN192159B (en) 2000-05-15 2004-02-28 Ranbaxy Lab Ltd
DE10029201A1 (en) * 2000-06-19 2001-12-20 Basf Ag Retarded release oral dosage form, obtained by granulating mixture containing active agent and polyvinyl acetate-polyvinyl pyrrolidone mixture below the melting temperature
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
WO2002024174A2 (en) 2000-09-22 2002-03-28 Galephar M/F Sustained release composition containing clarithromycin
GB0025208D0 (en) * 2000-10-13 2000-11-29 Euro Celtique Sa Delayed release pharmaceutical formulations
ATE266407T1 (en) 2000-10-30 2004-05-15 Lupin Ltd RAPIDLY DISRUPTING MEDICINAL COMPOSITION CONTAINING CEFUROXIM AXETIL WITH DELAYED RELEASE
CA2359812C (en) 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
SE0004671D0 (en) * 2000-12-15 2000-12-15 Amarin Dev Ab Pharmaceutical formulation
US6287599B1 (en) 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
CA2350195C (en) * 2000-12-20 2003-06-10 Duchesnay Inc. Rapid onset formulation of pyridoxine hydrochloride and doxylamine succinate
AU2002248792B2 (en) 2001-04-18 2006-09-21 Nostrum Pharmaceuticals Inc. A novel coating for a sustained release pharmaceutical composition
US20040022853A1 (en) * 2001-04-26 2004-02-05 Control Delivery Systems, Inc. Polymer-based, sustained release drug delivery system
JP4310605B2 (en) 2001-05-25 2009-08-12 大塚製薬株式会社 Pharmaceutical composition
AU2002314968B2 (en) 2001-06-08 2006-12-07 Endo Pharmaceuticals, Inc. Controlled release dosage forms using acrylic polymer, and process for making the same
US6693769B2 (en) * 2001-06-18 2004-02-17 Hitachi Global Storage Technologies Netherlands B.V. High data rate write head
EP1404300B1 (en) * 2001-06-22 2009-09-30 Pfizer Products Inc. Pharmaceutical compositions of dispersions of drugs and neutral polymers
JP3474870B2 (en) * 2001-08-08 2003-12-08 菱計装株式会社 Elevator
JP4848101B2 (en) 2001-08-17 2011-12-28 株式会社フジモト・コーポレーション Sustained release micropellet
EA200400343A1 (en) * 2001-08-29 2004-08-26 Рэнбакси Лабораториз Лимитед COMPOSITION WITH CONTROLLED SURVIVAL OF CLARITROMYCIN OR TINIDAZOL
WO2003017981A1 (en) * 2001-08-29 2003-03-06 Ranbaxy Laboratories Limited Controlled release formulation of clarithromycin or tinidazol
SI1446119T1 (en) * 2001-09-18 2006-08-31 Nycomed Danmark Aps Compositions comprising ipatropium and xylometazoline for treatment of the common cold
US20040234602A1 (en) 2001-09-21 2004-11-25 Gina Fischer Polymer release system
EP1438028A1 (en) 2001-09-28 2004-07-21 McNEIL-PPC, INC. Modified release dosage forms
US20050191359A1 (en) 2001-09-28 2005-09-01 Solubest Ltd. Water soluble nanoparticles and method for their production
WO2003028660A2 (en) * 2001-10-04 2003-04-10 Case Western Reserve University Drug delivery devices and methods
US6592901B2 (en) 2001-10-15 2003-07-15 Hercules Incorporated Highly compressible ethylcellulose for tableting
AUPR839001A0 (en) * 2001-10-19 2001-11-15 Eli Lilly And Company Dosage form, device and methods of treatment
WO2003039530A1 (en) 2001-11-07 2003-05-15 Synthon B.V. Tamsulosin tablets
US20050163846A1 (en) 2001-11-21 2005-07-28 Eisai Co., Ltd. Preparation composition containing acid-unstable physiologically active compound, and process for producing same
CN101982199A (en) 2001-11-21 2011-03-02 卫材R&D管理有限公司 Compositions containing acid-unstable physiologically active compounds and process for producing the same
WO2003053402A1 (en) * 2001-12-20 2003-07-03 Pharmacia Corporation Zero-order sustained released dosage forms and method of making the same
KR100540035B1 (en) 2002-02-01 2005-12-29 주식회사 태평양 Multi-stage oral drug controlled-release system
EP1481689A4 (en) * 2002-02-07 2005-10-05 Eisai Co Ltd Hair growth stimulants, percutaneous preparations and method of stimulating hair growth
HRP20020124A2 (en) * 2002-02-11 2003-10-31 Pliva D D Sustained/controlled release solid formulation as a novel drug delivery system with reduced risk of dose dumping
GB0203296D0 (en) 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
JP4355925B2 (en) * 2002-02-21 2009-11-04 大塚製薬株式会社 Sustained release formulation and method for producing the same
DE10208344A1 (en) 2002-02-27 2003-09-04 Roehm Gmbh Melt extrusion of active ingredient salts
GB0204772D0 (en) * 2002-02-28 2002-04-17 Phoqus Ltd Pharmaceutical dosage forms
ITMI20020515A1 (en) 2002-03-12 2003-09-12 Jagotec Ag SYSTEM FOR THE CONTROLLED RELEASE OF ONE OR MORE ACTIVE INGREDIENTS
JP5105684B2 (en) 2002-03-15 2012-12-26 大塚製薬株式会社 Sustained pharmaceutical formulation
FR2838647B1 (en) 2002-04-23 2006-02-17 PROLONGED RELEASE PARTICLES, PROCESS FOR THEIR PREPARATION AND TABLETS CONTAINING SAME
WO2003090723A1 (en) * 2002-04-23 2003-11-06 Bristol-Myers Squibb Company Modified-release vasopeptidase inhibitor formulation, combinations and method
WO2003096874A2 (en) 2002-05-15 2003-11-27 Sun Pharmaceutical Industries Limited Coated sustained release tablets of a hygroscopic compound for once-a-day therapy
DE10224170A1 (en) 2002-05-31 2003-12-11 Desitin Arzneimittel Gmbh Retarded release pharmaceutical composition, obtained without use of organic solvents or water by densifying mixture of active agent and retarding polymer in heated rollers
US20050158380A1 (en) 2002-06-07 2005-07-21 Manish Chawla Sustained release oral dosage forms of gabapentin
SI21223A (en) 2002-06-19 2003-12-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Pharmaceutical composition with stabilised amorphous donepezil,chloride
IL150509A (en) * 2002-07-01 2007-07-04 Joseph Kaspi Pharmaceutical compositions containing donepezil hydrocholoride
US20060002997A1 (en) 2002-08-23 2006-01-05 Puneet Shamar Nitrofurantoin controlled release dosage form
US20040052844A1 (en) * 2002-09-16 2004-03-18 Fang-Hsiung Hsiao Time-controlled, sustained release, pharmaceutical composition containing water-soluble resins
US20050048119A1 (en) * 2002-09-20 2005-03-03 Avinash Nangia Controlled release composition with semi-permeable membrane and poloxamer flux enhancer
EP1556019A2 (en) * 2002-10-24 2005-07-27 Merz Pharma GmbH & Co. KGaA Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
DE60318237T2 (en) 2002-10-24 2008-12-18 Immupharm A/S PHARMACEUTICAL COMPOSITIONS CONTAINING FLAVONOIDS AND MENTHOL
US20040162263A1 (en) 2002-10-31 2004-08-19 Supergen, Inc., A Delaware Corporation Pharmaceutical formulations targeting specific regions of the gastrointesinal tract
US7988993B2 (en) 2002-12-09 2011-08-02 Andrx Pharmaceuticals, Inc. Oral controlled release dosage form
AU2003299819A1 (en) * 2002-12-23 2004-07-22 Human Genome Sciences, Inc. Neutrokine-alpha conjugate, neutrokine-alpha complex, and uses thereof
US7910128B2 (en) 2003-01-03 2011-03-22 Supernus Pharmaceuticals, Inc. Use of a mixture of two or more enteric materials to regulate drug release via membrane or matrix for systemic therapeutics
WO2004066983A2 (en) 2003-01-24 2004-08-12 Control Delivery Systems, Inc. Controlled release of highly soluble agents
US20040258752A1 (en) 2003-01-31 2004-12-23 Paruthi Manoj Kumar Taste masking pharmaceutical composition and process for its preparation
US20040185097A1 (en) 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
IL154370A0 (en) * 2003-02-10 2003-09-17 Chemagis Ltd Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same
US7439365B2 (en) * 2003-11-17 2008-10-21 Usv, Ltd. Pharmaceutical salt of (1-benzyl-4-[(5,6-dimethoxy-1-indanone)-2-yl] methyl piperidine (Donepezil)
AR043467A1 (en) 2003-03-05 2005-07-27 Osmotica Argentina S A DRUG COMBINATION FOR MOTOR DYSFUNCTION IN PARKINSON'S DISEASE
JP4933033B2 (en) * 2003-03-17 2012-05-16 武田薬品工業株式会社 Controlled release composition
EP1607088B1 (en) * 2003-03-17 2019-02-27 Takeda Pharmaceutical Company Limited Controlled release composition
US20060210633A1 (en) 2003-04-03 2006-09-21 Sun Pharmaceutical Industries Limited Programmed drug delivery system
CA2520321A1 (en) 2003-04-04 2004-10-14 Pharmacia Corporation Oral extended release compressed tablets of multiparticulates
US20040208928A1 (en) 2003-04-15 2004-10-21 Animal Technology Institute Taiwan Method for preparing an orally administrable formulation for controlled release
US20040265375A1 (en) 2003-04-16 2004-12-30 Platteeuw Johannes J. Orally disintegrating tablets
US20040208932A1 (en) 2003-04-17 2004-10-21 Ramachandran Thembalath Stabilized paroxetine hydrochloride formulation
JP2004339162A (en) 2003-05-16 2004-12-02 Shin Etsu Chem Co Ltd Pharmaceutical solid preparation containing sparingly soluble medicine and method for producing the same
WO2004103342A2 (en) 2003-05-16 2004-12-02 Alkermes Controlled Therapeutics, Inc. Injectable sustained release compositions
CA2529746C (en) * 2003-06-16 2010-08-03 Andrx Pharmaceuticals, Llc Oral extended-release composition
BRPI0411451A (en) 2003-06-16 2006-07-18 Allergan Inc oral dosage forms of memantine
RU2375048C2 (en) * 2003-07-17 2009-12-10 Д-Р Редди'С Лабораторис Инк. Pharmacological composition with swelling coating
US20050013863A1 (en) * 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
US20050025829A1 (en) * 2003-07-29 2005-02-03 Kim Cherng-Ju Controlled drug release tablets
CA2534920A1 (en) * 2003-08-06 2005-02-24 Alza Corporation Uniform delivery of topiramate over prolonged period of time with enhanced dispersion formulation
EP1658048A2 (en) * 2003-08-22 2006-05-24 ALZA Corporation Stepwise delivery of topiramate over prolonged period of time
US8389008B2 (en) * 2003-09-19 2013-03-05 Penwest Pharmaceuticals Co. Delayed release dosage forms
ATE504288T1 (en) * 2003-09-26 2011-04-15 Alza Corp OROS PUSH STICK FOR THE CONTROLLED DELIVERY OF ACTIVE INGREDIENTS
EP1523979A1 (en) * 2003-10-13 2005-04-20 Wyeth Extended release pharmaceutical dosage form
US20050084531A1 (en) * 2003-10-16 2005-04-21 Jatin Desai Tablet with aqueous-based sustained release coating
US20050129751A1 (en) * 2003-12-16 2005-06-16 Rothenberg Barry E. Drug delivery compositions and methods
US20050129759A1 (en) * 2003-12-16 2005-06-16 Milan Sojka Sustained release compositions and controlled delivery method
US20050169992A1 (en) 2003-12-23 2005-08-04 Frank Jao Methods and dosage forms for increasing solubility of drug compositions for controlled delivery
US20050175696A1 (en) 2003-12-29 2005-08-11 David Edgren Drug granule coatings that impart smear resistance during mechanical compression
CA2552221A1 (en) 2003-12-31 2005-07-21 Actavis Group Hf Donepezil formulations
EP1763337A2 (en) * 2003-12-31 2007-03-21 Actavis Group HF Immediate, controlled and sustained release formulations of galanthamine
US20050163843A1 (en) 2003-12-31 2005-07-28 Garth Boehm Alprazolam formulations
JP2007519724A (en) 2004-01-26 2007-07-19 シヴィダ・インコーポレイテッド Controlled and sustained delivery of therapeutic agents based on nucleic acids
US7670624B2 (en) 2004-01-29 2010-03-02 Astella Pharma Inc. Gastrointestinal-specific multiple drug release system
US20050181044A1 (en) 2004-02-18 2005-08-18 Jaime Romero Compositions and methods for timed release of water-soluble nutritional supplements, green coffee extract
US20050181047A1 (en) 2004-02-18 2005-08-18 Jaime Romero Compositions and methods for timed release of water-soluble nutritional supplements
US20050186275A1 (en) 2004-02-23 2005-08-25 Standard Chem. & Pharm. Co. Ltd. Sustained release tamsulosin formulations
TW200534879A (en) 2004-03-25 2005-11-01 Bristol Myers Squibb Co Coated tablet formulation and method
NZ549838A (en) 2004-03-26 2010-04-30 Eisai R&D Man Co Ltd Coated controlled-release preparation containing a gastric acid secretion inhibitor
US20050220875A1 (en) 2004-03-31 2005-10-06 Agency For Science, Technology And Research Sustained-release tablet formulation
US20050220877A1 (en) 2004-03-31 2005-10-06 Patel Ashish A Bilayer tablet comprising an antihistamine and a decongestant
US8535716B2 (en) 2004-04-01 2013-09-17 Tsrl, Inc. Methods and composition of extended delivery of water insoluble drugs
US20050226929A1 (en) 2004-04-12 2005-10-13 Jianbo Xie Controlled release opioid analgesic formulation
US8058291B2 (en) 2005-04-06 2011-11-15 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of CNS-related conditions
US7619007B2 (en) * 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
WO2006063025A1 (en) * 2004-12-07 2006-06-15 Nektar Therapeutics Stable non-crystalline formulation comprising donepezil
US20060246003A1 (en) 2004-12-27 2006-11-02 Eisai Co. Ltd. Composition containing anti-dementia drug
US20060280789A1 (en) 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
US20090208579A1 (en) 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
MX2007007836A (en) 2004-12-27 2007-08-20 Eisai R&D Man Co Ltd Method for stabilizing anti-dementia drug.
US20090023778A1 (en) 2005-04-28 2009-01-22 Eisai R&D Management Co., Ltd. Composition Containing Anti-Dementia Drug
CN1709229A (en) 2005-06-10 2005-12-21 北京阜康仁生物制药科技有限公司 Memantine hydrochloride orally disintegrating tablet and its preparing method

Also Published As

Publication number Publication date
RU2401125C2 (en) 2010-10-10
NZ555693A (en) 2010-10-29
WO2006070930A1 (en) 2006-07-06
KR20070086667A (en) 2007-08-27
KR100866720B1 (en) 2008-11-05
BRPI0518396A2 (en) 2008-11-18
EP1830886B1 (en) 2016-04-13
IL183650A0 (en) 2007-09-20
NO20073482L (en) 2007-09-27
RU2007128767A (en) 2009-02-10
EP1830886A1 (en) 2007-09-12
US8481565B2 (en) 2013-07-09
MX2007007836A (en) 2007-08-20
US20100152164A1 (en) 2010-06-17
JP5514249B2 (en) 2014-06-04
JP2008525313A (en) 2008-07-17
IL183650A (en) 2013-12-31
AU2005320547A1 (en) 2006-07-06
AU2005320547B2 (en) 2009-02-05
US20080213368A1 (en) 2008-09-04
JP2012144568A (en) 2012-08-02
CA2592605C (en) 2010-12-07
HK1112399A1 (en) 2008-09-05
US8507527B2 (en) 2013-08-13
EP1830886A4 (en) 2012-10-10

Similar Documents

Publication Publication Date Title
CA2592605A1 (en) Method for stabilizing anti-dementia drug
CA2478558C (en) Naltrexone hydrochloride compositions
KR101708538B1 (en) Methods for treating cardiovascular disorders
AU2008304033B2 (en) Pharmaceutical composition containing esomeprazole
US9011912B2 (en) Extended-release oral dosage forms for poorly soluble amine drugs
KR20120064141A (en) Coated tablet formulation and method
JP5208209B2 (en) Donepezil-containing patch preparation and its package
CN102743330A (en) Pharmaceutical composition
JP2014517843A (en) Compressed core for pharmaceutical composition
PL205109B1 (en) Multiparticulate modified release composition
US20120107400A1 (en) Sustained release composition of theraputic agent
CA2275604A1 (en) Sustained release cisapride mini-tablet formulation
EP2172200A1 (en) Coated preparation
KR102408645B1 (en) Improved stability double-coated tablet Composition including S-omeprazole and manufacturing method thereof
WO2015145462A1 (en) Pharmaceutical compositions of dabigatran
WO2005027880A1 (en) Enteric soft gelatin capsule containing esomeprazole and method of preparation
CA2474246A1 (en) Alkylammonium salts of omeprazole and esomeprazole
JP2003500348A (en) Multiparticulate controlled release selective serotonin reuptake inhibitor formulation
AU776384B2 (en) Stable galenic preparations comprising a benzimidazol and method for the production thereof
WO2016102705A1 (en) Pharmaceutical composition comprising candesartan or pharmaceutically acceptable salts or esters thereof and amlodipine or pharmaceutically acceptable salts thereof
KR20220104705A (en) Tetrabenazine Transdermal Delivery Device
KR100983655B1 (en) Oral Formulations of Benzimidazole Derivatives
KR20210137161A (en) Improved API stability of softgels
CN111789808A (en) Oral pharmaceutical composition and structure thereof
NZ621666B2 (en) Methods for treating cardiovascular disorders

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20191227